Based on its unique metabolic regulation, inflammation inhibition, and appetite and gastrointestinal function regulation, Cagrlintide has shown significant potential for auxiliary regulation of gastrointestinal dysfunction, potential intervention in other digestive system diseases, and auxiliary improvement of recovery status in myocardial infarction patients
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in endocrinology vol
Pregnant or lactating women, diabetics, hypoglycemics and people with known medical conditions and/or taking drugs should consult with a licensed physician and/or pharmacist prior to taking dietary supplements
These results highlight the superior wound healing ability of G/D-CuP, with healed tissue resembling healthy skin, surpassing outcomes from other treatments
